GlobalAccess Eurp ex-UK Alpha I Acc USDH |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | -1.0 | 36.1 | -7.6 | 15.5 | 8.8 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 16/05/2024 | USD 5.73 | |
Day Change | -0.51% | |
Morningstar Category™ | Other Equity | |
ISIN | IE00B5WBVB38 | |
Fund Size (Mil) 30/04/2024 | EUR 100.06 | |
Share Class Size (Mil) 30/04/2024 | USD 0.08 | |
Max Initial Charge | - | |
Ongoing Charge 15/02/2024 | 1.39% |
Investment Objective: GlobalAccess Eurp ex-UK Alpha I Acc USDH |
The Fund seeks superior long-term capital growth primarily through investment in companies of European Countries, excluding the UK. The Fund is actively managed. The Fund invests primarily in common stock, preferred shares and securities convertible into common stock, of established companies domiciled or having significant operations (and listed or traded on a Regulated Market) in a range of European Countries, excluding the UK. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ian Aylward 01/03/2019 | ||
Inception Date 21/02/2014 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe Ex UK NR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for GlobalAccess Eurp ex-UK Alpha I Acc USDH | 30/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 3.74 |
ASML Holding NV | Technology | 3.00 |
Lvmh Moet Hennessy Louis Vuitton SE | Consumer Cyclical | 2.58 |
UniCredit SpA | Financial Services | 2.30 |
Sanofi SA | Healthcare | 2.28 |
Increase Decrease New since last portfolio | ||
GlobalAccess Eurp ex-UK Alpha I Acc USDH |